Cargando…

Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era

PURPOSE OF REVIEW: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers. RECENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Fasano, Genevieve A., Bayard, Solange, Gillot, Tamika, Hannibal, Zuri, Pedreira, Marian, Newman, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735127/
https://www.ncbi.nlm.nih.gov/pubmed/36530340
http://dx.doi.org/10.1007/s12609-022-00469-9
_version_ 1784846695687782400
author Fasano, Genevieve A.
Bayard, Solange
Gillot, Tamika
Hannibal, Zuri
Pedreira, Marian
Newman, Lisa
author_facet Fasano, Genevieve A.
Bayard, Solange
Gillot, Tamika
Hannibal, Zuri
Pedreira, Marian
Newman, Lisa
author_sort Fasano, Genevieve A.
collection PubMed
description PURPOSE OF REVIEW: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers. RECENT FINDINGS: A large body of literature demonstrates disparities in time to treatment for breast cancer, and most studies show that Black women receive treatment later than their White counterparts. The COVID-19 pandemic has been projected to worsen these disparities, but the extent of this impact remains unknown. SUMMARY: In this review, we describe the available evidence on disparities in time to treatment, potential drivers, and possible mitigation strategies. Future research must address how the COVID-19 pandemic has impacted the timely treatment of breast cancer patients, particularly populations vulnerable to disparate outcomes. Improved access to multidisciplinary breast programs, patient navigation services, and establishment of standards for timely treatment are necessary.
format Online
Article
Text
id pubmed-9735127
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-97351272022-12-12 Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era Fasano, Genevieve A. Bayard, Solange Gillot, Tamika Hannibal, Zuri Pedreira, Marian Newman, Lisa Curr Breast Cancer Rep Breast Cancer Disparities (LA Newman, Section Editor) PURPOSE OF REVIEW: Despite significant advances in detection and treatment for breast cancer, the breast cancer mortality rate for Black women remains 40% higher than that for White women. Timely work-up and treatment improve outcomes, yet no gold standard exists for which to guide providers. RECENT FINDINGS: A large body of literature demonstrates disparities in time to treatment for breast cancer, and most studies show that Black women receive treatment later than their White counterparts. The COVID-19 pandemic has been projected to worsen these disparities, but the extent of this impact remains unknown. SUMMARY: In this review, we describe the available evidence on disparities in time to treatment, potential drivers, and possible mitigation strategies. Future research must address how the COVID-19 pandemic has impacted the timely treatment of breast cancer patients, particularly populations vulnerable to disparate outcomes. Improved access to multidisciplinary breast programs, patient navigation services, and establishment of standards for timely treatment are necessary. Springer US 2022-12-06 2022 /pmc/articles/PMC9735127/ /pubmed/36530340 http://dx.doi.org/10.1007/s12609-022-00469-9 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Breast Cancer Disparities (LA Newman, Section Editor)
Fasano, Genevieve A.
Bayard, Solange
Gillot, Tamika
Hannibal, Zuri
Pedreira, Marian
Newman, Lisa
Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era
title Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era
title_full Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era
title_fullStr Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era
title_full_unstemmed Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era
title_short Disparities in Time to Treatment for Breast Cancer: Existing Knowledge and Future Directions in the COVID-19 Era
title_sort disparities in time to treatment for breast cancer: existing knowledge and future directions in the covid-19 era
topic Breast Cancer Disparities (LA Newman, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735127/
https://www.ncbi.nlm.nih.gov/pubmed/36530340
http://dx.doi.org/10.1007/s12609-022-00469-9
work_keys_str_mv AT fasanogenevievea disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era
AT bayardsolange disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era
AT gillottamika disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era
AT hannibalzuri disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era
AT pedreiramarian disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era
AT newmanlisa disparitiesintimetotreatmentforbreastcancerexistingknowledgeandfuturedirectionsinthecovid19era